scholarly journals Naloxone precipitated withdrawal increases dopamine release in the dorsal striatum of opioid dependent men

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ehsan Shokri-Kojori ◽  
Gene-Jack Wang ◽  
Nora D. Volkow

AbstractDopamine (DA) neurotransmission is critical in the neurobiology of reward and aversion, but its contribution to the aversive state of opioid withdrawal remains unknown in humans. To address this, we used updated voxelwise methods and retrospectively analyzed a [11C]raclopride-PET dataset to measure D2/3 receptor availability and relative cerebral blood flow (R1) in male opioid use disorder (OUD) participants (n = 10) during placebo and acute opioid withdrawal conditions. We found that acute withdrawal precipitated by the opioid antagonist naloxone significantly increased dorsal striatal DA release in OUD participants (pFWE < 0.05). Net changes in striatal DA were significantly correlated with a subjective index of withdrawal aversion such that greater DA increases were associated with more aversive responses (r(8) = 0.82, p < 0.005). Withdrawal also affected brain function, as indexed by increases in relative cerebral blood flow in the insula and putamen (pFWE < 0.05). Our findings are different from preclinical studies that have primarily reported decreases in ventral striatal DA during naloxone precipitated withdrawal, whereas this effect was not significant in OUD participants (p = 0.79). In sum, we provide evidence for the contribution of increases in dorsal striatal DA to the aversive state of naloxone precipitated withdrawal in humans.

2020 ◽  
Vol 185 (9-10) ◽  
pp. e1872-e1875
Author(s):  
Kathryn R Kinasz ◽  
Ellen D Herbst ◽  
Raj K Kalapatapu

Abstract Buprenorphine induction can lead to precipitated opioid withdrawal, even when using novel techniques such as transdermal buprenorphine. Involuntary limb movements are a distressing symptom of precipitated withdrawal that can be difficult to treat. We report a case of a military veteran transitioning from methadone to buprenorphine for the treatment of opioid use disorder (OUD) using small doses of transdermal buprenorphine. Herein, we review the literature associated with opioid withdrawal-related restlessness. Despite the known risk of concurrent benzodiazepine and buprenorphine administration, including decreased respiratory rate and death, we present a clinical presentation in which this medication combination may be necessary while under medical supervision. We suggest a stepwise algorithm for pharmacotherapy in patients experiencing involuntary limb movements associated with precipitated withdrawal. To safeguard the success of medication-assisted treatment (MAT) for opioid addiction, clinicians should be aware of potential clinical challenges when managing precipitated opioid withdrawal in patients with complex psychiatric comorbidities.


Genomics ◽  
2021 ◽  
Author(s):  
Uppala Radhakrishna ◽  
Swapan K. Nath ◽  
Sangeetha Vishweswaraiah ◽  
Lavanya V. Uppala ◽  
Ariadna Forray ◽  
...  

1969 ◽  
pp. 209-212 ◽  
Author(s):  
A. A. Hadjidimos ◽  
M. Brock ◽  
P. Baum ◽  
K. Schürmann

2019 ◽  
Vol 74 (3) ◽  
pp. 430-432 ◽  
Author(s):  
Reid H. Phillips ◽  
Matthew Salzman ◽  
Rachel Haroz ◽  
Rachel Rafeq ◽  
Anthony J. Mazzarelli ◽  
...  

NeuroImage ◽  
2019 ◽  
Vol 193 ◽  
pp. 157-166 ◽  
Author(s):  
Fan Nils Yang ◽  
Sihua Xu ◽  
Andrea Spaeth ◽  
Olga Galli ◽  
Ke Zhao ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document